Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model

Introduction: Respiratory diseases encompass a diverse range of conditions that significantly impact global morbidity and mortality. While common diseases like asthma and COPD exhibit moderate symptoms, less prevalent conditions such as pulmonary hypertension and cystic fibrosis profoundly affect qu...

Descripción completa

Detalles Bibliográficos
Autores: Zarate Tamames, Borja, Garin, Noé, Calvin Lamas, Marta, Jornet, Sonia, Martínez Simón, José J., Garcia-Gil, Sara, García Rebolledo, Eva M., Morillo Verdugo, Ramón Alejandro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/170960
Acceso en línea:https://hdl.handle.net/11441/170960
https://doi.org/10.3389/fphar.2024.1461473
Access Level:acceso abierto
Palabra clave:Adherence
Behavior
Hospital pharmacy
Innovation
Pharmaceutical care
Respiratory diseases
id ES_f4bf95ddcfb0093cd98311b5cc4e1b87
oai_identifier_str oai:idus.us.es:11441/170960
network_acronym_str ES
network_name_str España
repository_id_str
spelling Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care ModelZarate Tamames, BorjaGarin, NoéCalvin Lamas, MartaJornet, SoniaMartínez Simón, José J.Garcia-Gil, Sara García Rebolledo, Eva M.Morillo Verdugo, Ramón AlejandroAdherenceBehaviorHospital pharmacyInnovationPharmaceutical careRespiratory diseasesIntroduction: Respiratory diseases encompass a diverse range of conditions that significantly impact global morbidity and mortality. While common diseases like asthma and COPD exhibit moderate symptoms, less prevalent conditions such as pulmonary hypertension and cystic fibrosis profoundly affect quality of life and mortality. The prevalence of these diseases has surged by approximately 40% over the past 3 decades. Despite advancements in pharmacotherapy, challenges in drug administration, adherence, and adverse effects persist. This study aimed to develop and perform an interim validation of a Capacity-Motivation-Opportunity (CMO) model tailored for respiratory outpatients to enhance pharmaceutical care, which is the direct, responsible provision of medication-related care for the purpose of achieving definite outcomes that improve a patient’s quality of life, and overall wellbeing. Methodology: This cross-sectional, multicenter study was conducted from March 2022 to March 2023. It comprised four phases: 1) forming an expert panel of 15 hospital pharmacists, 2) selecting respiratory pathologies based on prevalence and severity, 3) developing the CMO model’s pillars, and 4) integrating and conducting an interim validation of the model. The Capacity pillar focused on patient stratification and personalized care; the Motivation pillar aligned therapeutic goals through motivational interviewing; and the Opportunity pillar promoted the use of information and communication technologies (ICTs) for telemedicine. Results: The model included eight respiratory diseases based on expert assessment. For the Capacity pillar, 22 variables were defined for patient stratification, leading to three priority levels for personalized pharmaceutical care. In a preliminary test involving 201 patients across six hospitals, the stratification tool effectively classified patients according to their needs. The Motivation pillar adapted motivational interviewing techniques to support patient adherence and behavior change. The Opportunity pillar established teleconsultation protocols and ICT tools to enhance patient monitoring and care coordination. Conclusion: The CMO model, tailored for respiratory patients, provides a comprehensive framework for improving pharmaceutical care. By focusing on patient-centered care, aligning therapeutic goals, and leveraging technology, this model addresses the multifaceted needs of individuals with respiratory conditions. Future studies are necessary to validate this model in other healthcare systems and ensure its broad applicability.Frontiers Media SAFarmacología2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/170960https://doi.org/10.3389/fphar.2024.1461473reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésFrontiers in Pharmacology, 15, 1461473.https://doi.org/10.3389/fphar.2024.1461473info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1709602026-06-17T12:51:07Z
dc.title.none.fl_str_mv Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
title Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
spellingShingle Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
Zarate Tamames, Borja
Adherence
Behavior
Hospital pharmacy
Innovation
Pharmaceutical care
Respiratory diseases
title_short Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
title_full Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
title_fullStr Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
title_full_unstemmed Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
title_sort Transforming Respiratory Diseases Management: a CMO-based Hospital Pharmaceutical Care Model
dc.creator.none.fl_str_mv Zarate Tamames, Borja
Garin, Noé
Calvin Lamas, Marta
Jornet, Sonia
Martínez Simón, José J.
Garcia-Gil, Sara
García Rebolledo, Eva M.
Morillo Verdugo, Ramón Alejandro
author Zarate Tamames, Borja
author_facet Zarate Tamames, Borja
Garin, Noé
Calvin Lamas, Marta
Jornet, Sonia
Martínez Simón, José J.
Garcia-Gil, Sara
García Rebolledo, Eva M.
Morillo Verdugo, Ramón Alejandro
author_role author
author2 Garin, Noé
Calvin Lamas, Marta
Jornet, Sonia
Martínez Simón, José J.
Garcia-Gil, Sara
García Rebolledo, Eva M.
Morillo Verdugo, Ramón Alejandro
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Farmacología
dc.subject.none.fl_str_mv Adherence
Behavior
Hospital pharmacy
Innovation
Pharmaceutical care
Respiratory diseases
topic Adherence
Behavior
Hospital pharmacy
Innovation
Pharmaceutical care
Respiratory diseases
description Introduction: Respiratory diseases encompass a diverse range of conditions that significantly impact global morbidity and mortality. While common diseases like asthma and COPD exhibit moderate symptoms, less prevalent conditions such as pulmonary hypertension and cystic fibrosis profoundly affect quality of life and mortality. The prevalence of these diseases has surged by approximately 40% over the past 3 decades. Despite advancements in pharmacotherapy, challenges in drug administration, adherence, and adverse effects persist. This study aimed to develop and perform an interim validation of a Capacity-Motivation-Opportunity (CMO) model tailored for respiratory outpatients to enhance pharmaceutical care, which is the direct, responsible provision of medication-related care for the purpose of achieving definite outcomes that improve a patient’s quality of life, and overall wellbeing. Methodology: This cross-sectional, multicenter study was conducted from March 2022 to March 2023. It comprised four phases: 1) forming an expert panel of 15 hospital pharmacists, 2) selecting respiratory pathologies based on prevalence and severity, 3) developing the CMO model’s pillars, and 4) integrating and conducting an interim validation of the model. The Capacity pillar focused on patient stratification and personalized care; the Motivation pillar aligned therapeutic goals through motivational interviewing; and the Opportunity pillar promoted the use of information and communication technologies (ICTs) for telemedicine. Results: The model included eight respiratory diseases based on expert assessment. For the Capacity pillar, 22 variables were defined for patient stratification, leading to three priority levels for personalized pharmaceutical care. In a preliminary test involving 201 patients across six hospitals, the stratification tool effectively classified patients according to their needs. The Motivation pillar adapted motivational interviewing techniques to support patient adherence and behavior change. The Opportunity pillar established teleconsultation protocols and ICT tools to enhance patient monitoring and care coordination. Conclusion: The CMO model, tailored for respiratory patients, provides a comprehensive framework for improving pharmaceutical care. By focusing on patient-centered care, aligning therapeutic goals, and leveraging technology, this model addresses the multifaceted needs of individuals with respiratory conditions. Future studies are necessary to validate this model in other healthcare systems and ensure its broad applicability.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/170960
https://doi.org/10.3389/fphar.2024.1461473
url https://hdl.handle.net/11441/170960
https://doi.org/10.3389/fphar.2024.1461473
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Frontiers in Pharmacology, 15, 1461473.
https://doi.org/10.3389/fphar.2024.1461473
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424500157710336
score 15,81155

Similares en LA Referencia